There were no differences for age, sex, myeloma type, International Staging System (ISS) stages, follow-up time, ECOG performance status, previous therapy type, or β2 microglobulin (β2M) levels between patients receiving original and generic lenalidomide. Here, HLA-G is linked to plasma cell myeloma.